DTU
DTU

Conference abstracts (178 of 178)

Years :

Search conference abstracts :

2019

Diabetes UK Annual Professional Conference, Liverpool
Phenotypic features of patients with Type 2 diabetes at increased risk of severe hypoglycemic events occurring before or after cardiovascular events
E Standl , SR Stevens , Y Lokhnygina , JB Buse , AP Maggioni , RJ Mentz , AF Hernandez and RR Holman
Diabetic Medicine 2019;36:Suppl 1:131
[Abstract]

American College of Cardiology (ACC) Annual Scientific Sessions, New Orleans
Patients with diabetes and peripheral arterial disease: Results from the EXSCEL trial
Anish Badjatiya, Peter Merrill, John Buse, Shaun Goodman, Brian Katona, Nayyar Iqbal, Peter Ohman, Neha Pagidipati, Naveed Sattar, Rury Holman, Adrian Hernandez, Robert J. Mentz, Manesh Patel, Schuyler Jones
Journal of the American College of Cardiology 2019;73:9 (Suppl 1):2040
[Abstract]

American College of Cardiology (ACC) Annual Scientific Sessions, New Orleans
Associations between beta-blocker therapy and cardiovascular outcomes in patients with diabetes and established atherosclerotic cardiovascular disease: Insights from the TECOS study
Jay Shavadia, Yinggan Zheng, Jennifer B. Green, Paul Armstrong, Cynthia Westerhout, Darren McGuire, Matthew Roe, J. H. Cornel, Rury Holman, Eric D. Peterson
Journal of the American College of Cardiology 2019;73:9 (Suppl 1):138
[Abstract]

American College of Cardiology (ACC) Annual Scientific Sessions, New Orleans
Increased risk of severe hypoglycemic events before and after cardiovascular events in type 2 diabetes: Validation of a novel concept
Eberhard Standl, Susanna Stevens, Yuliya Lokhnygina, John Buse, Aldo Maggioni, Robert Mentz, Ambady Ramachandran, Adrian Hernandez, Rury Holman
Journal of the American College of Cardiology 2019;73:9 (Suppl 1):24
[Abstract]

2018

54th Annual Meeting of the European Association for the Study of Diabetes, Berlin
Potential impact of differential drop-in of open-label diabetes medications in EXSCEL
J.B. Buse, M.A. Bethel, R.A. Patel, S.R. Stevens, S.M. Gustavson, Y. Lokhnygina, A.F. Hernandez, R.R.Holman, for the EXSCEL Study Group
Diabetologia 2018;61:(Suppl 1):S21-S22
[Abstract]

54th Annual Meeting of the European Association for the Study of Diabetes, Berlin
Cardiovascular safety and efficacy of exenatide once-weekly in patients with moderate renal dysfunction in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
A.F. Hernandez, M.A. Bethel , G.L. Bakris , P. Merrill, S.M. Gustavson, B.G. Katona, P. Ohman, Y. Lokhnygina, R.J. Mentz, R.R. Holman
Diabetologia 2018;61:(Suppl 1):S38
[Abstract]

54th Annual Meeting of the European Association for the Study of Diabetes, Berlin
Comparison of medical resources, costs, and health utilities among patients with CHD and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation Trial (ACE)
L. Mc Morrow, F. Becker, J. Leal, A.M. Gray, R. Coleman, H.C. Gerstein, L. Rydèn, R.R. Holman
Diabetelogia 2018;61:(Suppl 1):S344
[Abstract]

54th Annual Meeting of the European Association for the Study of Diabetes, Berlin
Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial
F. Becker, H.Dakin, S.D.Reed, Y.Li, J. Leal, S.M. Gustavson, B.Kartman, E.Wittbrodt, A.M. Gray, A.F.Hernandez, R.R. Holman
Diabetelogia 2018;61:(Suppl 1):S366
[Abstract]

54th Annual Meeting of the European Association for the Study of Diabetes, Berlin
Changes in serum calcitonin concentrations and incidence of adjudicated medullary thyroid carcinoma in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
B. Katona, M.A. Bethel, R. Patel, V.P. Thompson, S.M. Gustavson, P. Ohman, N. Iqbal, J.B.Buse, A.F. Hernandez, R.R.Holman
Diabetelogia 2018;61:(Suppl 1):S376
[Abstract]

54th Annual Meeting of the European Association for the Study of Diabetes, Berlin
Impact of exenatide on medical costs and health utilities in type 2 diabetes: experience from EXSCEL
S.D. Reed, Y. Li, H. Dakin, F. Becker, J. Leal, S.M. Gustavson, B. Kartman, E. Wittbrodt, R.J. Mentz, N.J. Pagidipati, M.A. Bethel, A.M. Gray, R.R. Holman, A.F. Hernandez
Diabetelogia 2018;61:(Suppl 1):S426
[Abstract]

54th Annual Meeting of the European Association for the Study of Diabetes, Berlin
The effect of lixisenatide on post-prandial blood glucose and glucagon in type 1 diabetes
C. Ballav, A. Dhere, O. Agbaje, I. Kennedy, R.R. Holman, K.R. Owen
Diabetelogia 2018;61:(Suppl 1):S387
[Abstract]

54th Annual Meeting of the European Association for the Study of Diabetes, Berlin
Risk of cardiovascular disease in individuals with latent autoimmune diabetes of adults: results from the UKPDS
E. Maddaloni, R.L. Coleman, P. Pozzilli, R.R. Holman
Diabetelogia 2018;61:(Suppl 1):S574-5
[Abstract]

European Society of Cardiology (ESC) Congress 2018, Munich
Effects of once weekly exenatide on clinical outcomes in the subgroup of patients with preexisting cardiovascular disease: insights from EXSCEL
R.J. Mentz, V.P. Thompson, S.M. Gustavson, N. Iqbal, P. Ohman, R.R. Holman, A.F. Hernandez
European Heart Journal 2018;39:(Suppl 1):1082
[Abstract]

European Society of Cardiology (ESC) Congress 2018, Munich
LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS
G.M. De Ferrari, S.R. Stevens, G. Ambrosio, S. Leonard, D.K. McGuire, P.W. Armstrong, J.B. Green, M.A. Bethel, R.R. Holman, E.D. Peterson
European Heart Journal 2018;39:(Suppl 1):399-40
[Abstract]

European Society of Cardiology (ESC) Congress 2018, Munich
Cluster analysis of cardiovascular risk phenotypes in patients with type 2 diabetes and established atherosclerotic cardiovascular disease: a potential approach to precision medicine
A. Sharma, Y. Zheng, J.A. Ezekowitz, C.M. Westerhout, S.G. Goodman, P.W. Armstrong, J.B. Buse, J.B. Green, K.D. Kaufman, D.K. McGuire, G. Ambrosio, L.M. Chuang, R.D. Lopes, E.D. Peterson, R.R. Holman
European Heart Journal 2018;39:(Suppl 1):871
[Abstract]

American Diabetes Association (ADA) Conference, Orlando
Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
M. ANGELYN BETHEL, ROBERT J. MENTZ, PETER MERRILL, JOHN B. BUSE, JULIANA C. CHAN, SHAUN G. GOODMAN, NAYYAR IQBAL, NELI JAKUBONIENE, BRIAN G. KATONA, YULIYA LOKHNYGINA, RENATO D. LOPES, ALDO P. MAGGIONI, PETER K. OHMAN, NEIL R. POULTER, AMBADY RAMACHANDRAN, TSVETALINA TANKOVA, BERNARD ZINMAN, ADRIAN F. HERNANDEZ, RURY R. HOLMAN
Diabetes 2018;67:(Suppl 1):522-P
[Abstract]

American Diabetes Association (ADA) Conference, Orlando
EXSCEL-Once-Weekly Exenatide Reduces Medical Resource Utilization in Patients with Type 2 Diabetes Mellitus
SHELBY D. REED, YANHONG LI, HELEN A. DAKIN, FRAUKE BECKER, JOSE LEAL, STEPHANIE GUSTAVSON, BERNT KARTMAN, ERIC T. WITTBRODT, ROBERT J. MENTZ, NEHA PAGIDIPATI, M. ANGELYN BETHEL, ALASTAIR M. GRAY, RURY R. HOLMAN and ADRIAN F. HERNANDEZ
Diabetes 2018;67:(Suppl 1):1319-P
[Abstract]

American Diabetes Association (ADA) Conference, Orlando
Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group
LINDSAY CLEGG, HIDDO L. HEERSPINK, ROBERT C PENLAND, WEIFENG TANG, DAVID W BOULTON, SRINIVAS BACHINA, ROBERT D FOX, PETER FENICI, MARCUS THURESSON, ROBERT J MENTZ, ADRIAN F HERNANDEZ, M ANGELYN BETHEL, RURY R HOLMAN
Diabetes 2018;67:(Suppl 1):130-LB
[Abstract]

American Diabetes Association (ADA) Conference, Orlando
Cardiovascular Event Hazards over Time in TECOS
M. ANGELYN BETHEL, HARALD SOURIJ, SUSANNA R. STEVENS, YULIYA LOKHNYGINA, RENATO D. LOPES, AMANDA ADLER, DARREN K. MCGUIRE, ERIC PETERSON and RURY R. HOLMAN
Diabetes 2018;67:(Suppl 1):452-P
[Abstract]

American Diabetes Association (ADA) Conference, Orlando
Regional Variations in Case Fatality following a Major Coronary or Cerebrovascular Event in People with Type 2 Diabetes-Evidence from the ADVANCE Trial and TECOS Trial
PHILIP M. CLARKE, XINYANG HUA, JOHN CHALMERS, MARK WOODWARD, ESQ., RUTH L. COLEMAN, JENNIFER B. GREEN, DARREN K. MCGUIRE, RURY R. HOLMAN
Diabetes 2018;67:(Suppl 1):1299-P
[Abstract]

Diabetes Congress of the German Diabetes Association, Berlin
Effects of exenatide on cardiovascular outcomes in patients with type 2 diabetes mellitus: results of the EXSCEL study
Hanefeld M on behalf of EXSCEL Study Group
Diabetology and Metabolism 2018;13:Suppl 1:S70
[Abstract]

14th National Conference of the Primary Care Diabetes Society, Birmingham
Effects of once-weekly exenatide on clinical outcomes in the subgroup of patients with pre-existing cardiovascular disease: Insights from EXSCEL
Mentz RJ, on behalf of the EXSCEL Study Group
Diabetes and Primary Care 2018;20:Suppl A:3
[Abstract]

2017

Diabetes UK Annual Professional Conference, Manchester
Sensing hypoglycaemia at an earlier stage using an integrated physiological multi-signal data fusion approach
MJ Theodorakis, D Clifton, GW Colopy, J Jorge, A Dhere, C Ballav, I Kennedy, O Agbaje, L Tarassenko, RR Holman
Diabetic Medicine 2017;34 (Suppl 1):62-63
[Abstract]

Diabetes UK Annual Professional Conference, Manchester
Development of an online risk calculator to predict durability of good glycaemic control with sulfonylurea and thiazolidinedione therapy: a MASTERMIND stratified medicine study
JM Dennis, WE Henley, M Weedon, M Lonergan, AG Jones, N Sattar, RR Holman, ER Pearson, AT Hattersley, BM Shields and LR Rodgers
Diabetic Medicine 2017;34 (Suppl 1):5 - 35
[Abstract]

Diabetes UK Annual Professional Conference, Manchester
Predictors of response to SGLT2-inhibitors and DPP4-inhibitors: a MASTERMIND stratified medicine study
B Shields, J Dennis, W Henley, M Weedon, M Lonergan, A Jones, N Sattar, R Holman, E Pearson and A Hattersley
Diabetic Medicine 2017;34 (Suppl 1):5 - 35
[Abstract]

Diabetes UK Annual Professional Conference, Manchester
Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
RL Coleman, A Gray, UC Broedl, D Fitchett, JT George, HJ Woerle, B Zinman and RR Holman
Diabetic Medicine 2017;34 (Suppl 1):5 - 35
[Abstract]

Diabetes UK Annual Professional Conference, Manchester
Estimating the potential incremental benefits on Type 2 diabetes complications rates of targeting successively lower LDL-cholesterol levels
SA Mostafa, RL Coleman, OF Agbaje, A Gray, RR Holman and MA Bethel
Diabetic Medicine 2017;34 (Suppl 1):36-194
[Abstract]

53rd EASD Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Time to insulin in the Trial Evaluating Cardiovascular Outomes with Sitagliptin (TECOS)
S.S. Engel, M.A. Bethel, J. Garg, S.R. Stevens, Y. Lokhnygina3, R.G. Josse4, J.B. Green, E.D. Peterson, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S3
[Abstract]

53rd EASD Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes
O.F. Agbaje, R.L. Coleman, A.T. Hattersley, E.Z. Pearson, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S300
[Abstract]

53rd EASD Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Risk of anaemia with long-term metformin use in a community setting
L.A. Donnelly, K. Gardner, R.L. Coleman, N. Sattar, A.T. Hattersley, R.R. Holman, E.R. Pearson
Diabetelogia 2017;60:(Suppl 1):S139
[Abstract]

53rd EASD Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Associations between insulin dose titration over one year and hypoglycaemia: a descriptive study using 4-T data
A.J. Farmer, M.-M. Lee , J. Oke , A. Reutens , J. Shaw , R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S310
[Abstract]

53rd EASD Annual Meeting of the European Association for the Study of Diabetes, Lisbon
No major impact seen with sitagliptin on rates of cardiovascular death or hospitalisation for heart failure following myocardial infarction during TECOS
M.A. Nauck, K.S. Pieper, Y. Lokhnygina, D.K. McGuire, E.D. Peterson, R.R. Holman,
Diabetelogia 2017;60:(Suppl 1):S356
[Abstract]

53rd EASD Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Association between race and glycaemic response to sitagliptin: insights from TECOS
T.M.E. Davis, H. Mulder, Y. Lokhnygina, E. Standl, E.D. Peterson, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S356
[Abstract]

53rd EASD Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Resource use and UK-perspective costs in patients with type 2 diabetes during the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
A.M. Gray, J. Leal, S.D.Reed, Y. Li, F. Graham, J.B.Green, K.D. Kaufman, L. Radican, J. Alfredsson, J. Buse, A. Riefflin, F. Van de Werf, E.D. Peterson, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S357
[Abstract]

53rd EASD Annual Meeting of the European Association for the Study of Diabetes, Lisbon
A calculator to predict durability of HbA1c response with DPP4 inhibitors, sulfonylureas and thiazolidinediones: a MASTERMIND precision medicine study
J.M. Dennis, W.E. Henley, M.N. Weedon, M. Lonergan, L.R. Rodgers, A.G. Jones, N.A. Sattar, R.R. Holman, E.R. Pearson, A.T. Hattersley, B.M. Shields
Diabetelogia 2017;60:(Suppl 1):S388
[Abstract]

53rd EASD Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Predictors of response to SGLT2-inhibitors and DPP4-inhibitors
B.M. Shields, J. Dennis, W. Henley, M.Weedon, M. Lonergan, L. Rodgers, A. Jones, N. Sattar, R. Holman, E. Pearson, A. Hattersley
Diabetelogia 2017;60:(Suppl 1):S404
[Abstract]

53rd EASD Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
R.L. Coleman, A.M. Gray, U.C. Broedl, D. Fitchett, J.T. George, H.-J. Woerle, B. Zinman, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S522
[Abstract]

53rd EASD Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Modelling incremental benefits on macro- and micro-vascular complications rates when targeting lower systolic blood pressure levels in type 2 diabetes
S.A. Mostafa, R.L. Coleman, O.F. Agbaje, A. Gray, R.R. Holman, M.A. Bethel
Diabetelogia 2017;60:(Suppl 1):S525
[Abstract]

American Heart Association (AHA) Scientific Sessions 2017, Anaheim
Underuse of Oral Anticoagulation, High Use of Aspirin and Worse Clinical Outcomes in Patients With Type 2 Diabetes and Atrial Fibrillation: Insights From the TECOS Trial
Patricia Guimaraes, Renato D Lopes, Susanna R Stevens, Jennifer B Green, Darren K McGuire, Rury R Holman and Eric D Peterson, on behalf of the TECOS Study Group
Circulation 2017;136:Supp 1:
[Abstract]

American Heart Association (AHA) Scientific Sessions 2017, Anaheim
International Variation in Management and Clinical Outcome of Patients With Type 2 Diabetes and Heart Failure: Insights From TECOS
Ankeet S Bhatt, Nancy Luo, Nicole Solomon, Neha J Pagidipati, Giuseppe Ambrosio, Jennifer B Green, Darren K McGuire, Eberhard Standl, Jan H Cornel, Sigrun Halvorsen, Renato D Lopes, Harvey White, Rury R Holman, Eric D Peterson, and Robert J Mentz, on behalf of the TECOS Study Group
Circulation 2017;136:Suppl 1:
[Abstract]

American Heart Association (AHA) Scientific Sessions 2017, Anaheim
Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights From the EXSCEL Trial
Robert J Mentz, M. Angelyn Bethel, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Julian C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal, Aldo P Maggioni, Steven P Marso, Peter Öhman, Neha J Pagidipati, Neil Poulter, Ambady Ramachandran, Bernard Zinman, Rury R Holman, Adrian F Hernandez, on behalf of the EXSCEL Study Group
Circulation 2017;136:24:
[Abstract]

Association of British Clinical Diabetologists (ABCD) Autumn Meeting 2016, Brighton
Estimating the potential risk reduction of Type 2 diabetes mellitus (T2DM) complications if systolic blood pressure (SBP) targets were to be lowered
S Mostafa, RL Coleman, OF Agbaje, A Gray, RR Holman, MA Bethel
The British Journal of Diabetes 2017;17:1:42
[Abstract]

Quality of Care and Outcomes Research (QCOR) Scientific Sessions 2017, Arlington
Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes: International Insights From the TECOS Trial
Neha J Pagidipati, Ann Marie Navar, Karen S Pieper, Jennifer B Green, M. A Bethel, Paul W Armstrong, Robert G Josse, Darren K McGuire, Yuliya Lokhnygina, Jan H Cornel, Sigrun Halvorsen, Timo E Strandberg, Tuncay Delibasi, Rury R Holman, Eric D Peterson, on behalf of the TECOS Study Group
Circulation 2017;10:Suppl 3:
[Abstract]

European Society of Cardiology (ESC) Congress 2017,
Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes: International Insights From the TECOS Trial
Neha J Pagidipati, Ann Marie Navar, Karen S Pieper, Jennifer B Green, M. A Bethel, Paul W Armstrong, Robert G Josse, Darren K McGuire, Yuliya Lokhnygina, Jan H Cornel, Sigrun Halvorsen, Timo E Strandberg, Tuncay Delibasi, Rury R Holman, and Eric D Peterson, on behalf of the TECOS Study Group
Circulation 2017;10:Suppl 3:
[Abstract]

Francophone Society of Diabetes Annual Congress 2017, Lille
Evaluation of the Safety Profile of Sitagliptin in Older Adults in the TECOS Cardiovascular Safety Trial
Angelyn Bethel, Samuel Engel, Jennifer Green, Zhen Huang, Keith Kaufman, Eberhard Standl, Shailaja Suryawanshi, Frans Van de Werf, Eric Peterson, Rury Holman
Diabetes and Metabolism 2017;43:2 Suppl:A55-A56

Francophone Society of Diabetes Annual Congress 2017, Lille
Impact on cardiovascular events and tolerance of sitagliptin in insulin-treated patients with type 2 diabetes: the TECOS experiment
Angelyn Bethel, Sam Engel, Jie Ding, Robert Josse, Rury Holman
Diabetes and Metabolism 2017;43:2 Suppl:A56

Francophone Society of Diabetes Annual Congress 2017, Lille
Differences Between Men and Women in the Cardiovascular Safety Test of Sitagliptin (TECOS)
Jennifer Green, Joakim Alfredsson, Susanna Stevens, Shelby Reed, Darren McGuire, Paul Armstrong, Sam Engel, Angelyn Bethel, Frans Van de Werf, Eric Peterson, Rury Holman
Diabetes and Metabolism 2017;43:2 Suppl:A56

American Diabetes Association (ADA) Conference, San Diego-P
Medical Resource Use and Costs in Patients with Type 2 Diabetes Mellitus during the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
SHELBY D. REED, YANHONG LI, JOSE LEAL, FELICIA GRAHAM, JOAKIM ALFREDSSON, ALASTAIR M. GRAY, JOHN B. BUSE, JENNIFER B. GREEN, KEITH D. KAUFMAN, AXEL RIEFFLIN, SHAILAJA SURYAWANSHI, FRANS VAN DE WERF, ERIC D. PETERSON, RURY R. HOLMAN, TECOS STUDY GROUP
Diabetes 2017;66:(Suppl 1):A697-A750.
[Abstract]

American Diabetes Association (ADA) Conference, San Diego
Time to Insulin in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
M A BETHEL, SAMUEL S ENGEL, JYOTSNA GARG, SUSANNA R STEVENS, YULIYA LOKHNYGINA, ROBERT G JOSSE, JENNIFER B GREEN, ERIC D PETERSON, RURY R HOLMAN, TECOS STUDY GROUP
Diabetes 2017;66:(Suppl 1):1183-P
[Abstract]

American Diabetes Association (ADA) Conference, San Diego
Emerging Sitagliptin Benefit for All-Cause Hospitalizations: Evidence from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
SHELBY D REED, YANHONG LI, JOSE LEAL, FELICIA GRAHAM, JOAKIM ALFREDSSON, ALASTAIR M GRAY, JOHN B BUSE, JENNIFER B GREEN, KEITH D KAUFMAN, AXEL RIEFFLIN, SHAILAJA SURYAWANSHI, FRANS VAN DE WERF, ERIC D PETERSON, RURY R HOLMAN, FOR THE TECOS STUDY
Diabetes 2017;66:(Suppl 1):1344-P

2016

52nd Annual Meeting of the European Association for the Study of Diabetes, Munich
Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial
R.G. Josse, S.R. Majumdar, Y. Zheng, J.B. Buse, J.B. Green, K.D. Kaufman, E.D. Peterson, R.R.Holman, P.W. Armstrong, on behalf of the TECOS Study Group
Diabetologia 2016;59:Suppl 1:S372
[Abstract]

52nd Annual Meeting of the European Association for the Study of Diabetes, Munich
Impact of sitagliptin on cardiovascular and safety-related outcomes in insulin-treated type 2 diabetes: the TECOS experience
M.A. Bethel, S.S. Engel, J. Ding, R.G. Josse, R.R. Holman and the TECOS Study Group
Diabetologia 2016;59:Suppl 1:S369
[Abstract]

52nd Annual Meeting of the European Association for the Study of Diabete, Munich
Assessing the safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
S.S. Engel, S. Suryawanshi, R.G. Josse, E.D. Peterson, R.R. Holman and the TECOS Study Group
Diabetologia 2016;59:Suppl 1:S361
[Abstract]

52nd Annual Meeting of the European Association for the Study of Diabetes, Munich
Stimulatory effects of the long - acting kisspeptin analogue TAK - 448 on serum testosterone in men with type 2 diabetes and hypogonadotropic hypogonadism
J.T. George, J.E. Milton, A.E. Cooper, S. Greentree, R.A. Anderson and R.R. Holman
Diabetologia 2016;59:Suppl 1:S228-S229
[Abstract]

52nd Annual Meeting of the European Association for the Study of Diabetes, Munich
Estimated 10-year benefit for diabetes complication rates by 1% HbA1c decrements in people with type 2 diabetes and cardiovascular disease
S.A. Mostafa, R.R. Holman, R.L. Coleman, O. Agbaje, M.A. Bethel
Diabetologia 2016;59:Suppl 1:S543
[Abstract]

52nd Annual Meeting of the European Association for the Study of Diabetes, Munich
Sex differences in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
J.B. Green, J. Alfredsson, S.R. Stevens, S.D. Reed, D.K. McGuire, P.W. Armstrong, S.S. Engel, M.A. Bethel, F. Van de Werf, E.D. Peterson, R.R. Holman
Diabetologia 2016;59:Suppl 1:S544
[Abstract]

American Heart Association (AHA) Scientific Sessions 2016, New Orleans
Treated Systolic Blood Pressure and Cardiovascular Risk in Adults With Hypertension and Type 2 Diabetes: Results From the TECOS Trial
Ann M Navar, Dianne S Gallup, Yuliya Lokhnygina, Jennifer B Green, Darren K McGuire, Paul W Armstrong, John B Buse, Samuel S Engel, John M Lachin, Eberhard Standl, Frans Van de Werf, Rury R Holman, and Eric D Peterson
Circulation 2016;134:Suppl 1:
[Abstract]

Diabetes UK Annual Professional Conference, Glasgow
Stratification using gender and body mass index (BMI) results in better glycaemic control for longer: a MASTERMIND study
B Shields, J Dennis, L Rodgers, A Jones, M Lonergan, W Henley, R Holman, E Pearson, A Hattersley, and the MASTERMIND Consortium
Diabetic Medicine 2016;33:Suppl 1:10-11
[Abstract]

Diabetes UK Annual Professional Conference, Glasgow
Assessing the safety of sitagliptin in elderly participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin
MA Bethel, SS Engel, JB Green, Z Huang, KD Kaufman,E Standl, S Suryawanshi, F Van de Werf, ED Peterson, and RR Holman
Diabetic Medicine 2016;33:Suppl 1:86
[Abstract]

Diabetes UK Annual Professional Conference, Glasgow
Personalisation of treatment with metformin by age, weight and sex: a MASTERMIND study
ME Lonergan, B Shields, OF Agbaje, J Dennis, M Weeden, L Rodgers, RR Holman, A Hattersley and EW Pearson
Diabetic Medicine 2016;33:Suppl 1:194
[Abstract]

American Diabetes Association (ADA) Conference, New Orleans
Baseline Characteristics of Patients Enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
ROBERT MENTZ, M ANGELYN BETHEL, STEPHANIE GUSTAVSON, VIVIAN THOMPSON, JOHN B BUSE, JULIANA CHAN, ALDO P MAGGIONI, STEVEN P MARSO, PETER OHMAN, NEIL POULTER, AMBADY RAMACHANDRAN, BERNARD ZINMAN, NAYYAR IQBAL, ADRIAN F HERNANDEZ, RURY R HOLMAN
Diabetes 2016;65:(Suppl 1):1039-P
[Abstract]

American Diabetes Association (ADA) Conference, New Orleans
Assessing the Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
SAMUEL S ENGEL, SHAILAJA SURYAWANSHI, ROBERT G JOSSE, ERIC PETERSON, RURY R HOLMAN, TECOS STUDY GROUP
Diabetes 2016;65:(Suppl 1):1181-P
[Abstract]

American Diabetes Association (ADA) Conference, New Orleans
Personalizing Therapy in Type 2 Diabetes: The Effect of BMI and Gender on Response and Side Effects to Sulfonylureas and Thiazolidinediones Itinerary
JOHN M DENNIS, WILLIAM E HENLEY, MICHAEL N WEEDON, MICHAEL LONERGAN, LAUREN R RODGERS, ANGUS G JONES, RURY R HOLMAN, EWAN R PEARSON, ANDREW T HATTERSLEY, BEVERLEY M SHIELDS
Diabetes 2016;65:(Suppl 1):1541-P
[Abstract]

American Diabetes Association (ADA) Conference, New Orleans
Sitagliptin and Risk of Fractures in Type 2 Diabetes: Results from the TECOS Trial
ROBERT G JOSSE, SUMIT R MAJUMDAR, JOHN B BUSE, JENNIFER B GREEN, KEITH D KAUFMAN, CYNTHIA M WESTERHOUT, YINGGAN ZHENG, ERIC PETERSON, RURY R HOLMAN, PAUL W ARMSTRONG, TECOS STUDY GROUP
Diabetes 2016;65:(Suppl 1):587-P
[Abstract]

2015

American Diabetes Association (ADA) Conference, Boston
Reductions in hemoglobin and packed cell volume over 3 years in UKPDS patients with newly-diagnosed type 2 diabetes
Ruth L. Colman, Rury R. Holman
Diabetes 2015;64:1:A440

51st EASD Annual Meeting of the European Association for the Study of Diabetes, Stockholm
Evaluation of the one-year efficacy, safety and glycaemic effects of evolocumab (AMG 145) in 4,802 subjects with, at high risk for, or at low risk for, diabetes mellitus
N. Sattar, D. Preiss , D. Blom , C.S. Djedjos, M. Elliott , A. Pellacani, S.M. Wasserman, M. Koren, R. Holman
Diabetelogia 2015;58:(Suppl 1):S79
[Abstract]

51st EASD Annual Meeting of the European Association for the Study of Diabetes, Stockholm
Patient characteristics are associated with treatment response to second line glucose lowering therapy: a MASTERMIND study
B.M. Shields, M. Lonergan, J. Dennis, A. Jones, L. Rogers, M. Weedon, L. Donnelly, R. Holman, W. Henley, E. Pearson, A. Hattersley
Diabetelogia 2015;58:(Suppl 1):S405
[Abstract]

2014

American Diabetes Association (ADA) Conference, San Diego
Effects of Long-term, Monthly Administration of the PCSK9 Inhibitor Evolocumab in Patients with Dysglycemia or Metabolic Syndrome
Robert R. Henry, Rury R. Holman, Robert P. Giugliano, Frederick J. Raal, David Sullivan, Nariman Honarpour, Patric Nelson, Mary Elliott, Thomas Liu, Scott M. Wasserman, Michael J. Koren
Diabetes Care 2014;63 supp 1:A157

2012

American Diabetes Association (ADA) Conference, Philadelphia
Positive Impact of Revised FDA Guidance on Clinical Trial Design in Diabetes
Bethel MA, Sourij H
Diabetes 2012;61:Supp 1:A264
[Abstract]

American Diabetes Association (ADA) Conference, Philadelphia
Updated UKPDS Risk Engine that Estimates Primary and Secondary Cardiovascular Disease Risk in People With Recently-Diagnosed or Established Type 2 Diabetes
Coleman RL, Stevens RJ, Holman RR
Diabetes 2012;61:Supp 1:A103
[Abstract]

15th International & 14th European Congress of Endocrinology, Florence
Time course of the glucose legacy effect
R. Holman
Endocrine Abstracts 2012;29:S9.3

Diabetes UK Annual Professional Conference, Glasgow
A self-administered oral glucose tolerance test
MA Bethel, H Sourij, S White, L Tucker, I Kennedy, R Coleman, A Ring and RR Holman
Diabetic Medicine 2012;2012 Sup 1:47
[Abstract]

2011

39th Meeting of the British Society for Paediatric Endocrinology and Diabetes, London
Early intervention in type 2 diabetes mellitus
Rury Holman
Endocrine Abstracts 2011;27:S22

2010

Diabetes UK Annual Professional Conference, Liverpool
Challenges of Treating to Target - Experiences and views of patients and staff participating in the three-year 4-T trial
J Lawton, N Jenkins, A Farmer, N Hallowell, RR Holman
Diabetic Medicine 2010;27 Supp 1:21
[Abstract]

2009

Diabetes UK Annual Professional Conference, Glasgow
Addition of exenatide therapy to insulin treatment in individuals with type 2 diabetes
Price HC, Holman RR, Levy JC, Ayyagari U.
Diabetic Medicine 2009;26:Suppl 1:141
[Abstract]

Diabetes UK Annual Professional Conference, Glasgow
Addition of Exenatide therapy to oral blood glucose lowering treatment in individuals with Type 2 diabetes
Ayyagari U, Holman RR, Levy JC, Price HC
Diabetic Medicine 2009;26:Suppl 1:141
[Abstract]

69th Scientific Session of the American Diabetes Association, New Orleans
Unravelling the Dynamics of Insulin Dose and Changes in Weight and HbA1c
Paul SK, Holman RR
Diabetes 2009;58:Suppl 1:A163
[Abstract]

69th Scientific Session of the American Diabetes Association, New Orleans
Rationale and Design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
Bethel MA, Green J, Califf RM, Holman RR
Diabetes 2009;59:Suppl 1:A555
[Abstract]

69th Scientific Session of the American Diabetes Association, New Orleans
Physical Activity in Adults at High Risk of Cardiovascular Disease
Price HC, Griffin SJ, Holman RR
Diabetes 2009;58:Suppl 1:A587
[Abstract]

69th Scientific Session of the American Diabetes Association, New Orleans
Prevalence of Undiagnosed Dysglycaemia in Adults at High Risk of Cardiovascular Disease
Price HC, Griffin SJ, Holman RR
Diabetes 2009;58:Suppl 1:A639
[Abstract]

69th Scientific Session of the American Diabetes Association, New Orleans
Differences in Insulin Treatment Satisfaction Following Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Farmer AJ, Oke J, Stevens R, Holman RR
Diabetes 2009;58:Suppl 1:A130
[Abstract]

69th Scientific Session of the American Diabetes Association, New Orleans
Do Glycoalbumin Levels Preferentially Reflect Postprandial Glucose Excursions?
Hartweg J, Paul SJ, Fisher K, Carter R, Klyne R, Holman RR
Diabetes 2009;58:Suppl 1:A505
[Abstract]

2008

Diabetes UK Annual Professional Conference, Glasgow
The UKPDS Life Expectancy Calculator for Individuals with Type 2 diabetes
Price HC, Kennedy I, Clarke PM, Gray AM and Holman RR.
Diabetic Medicine 2008;25:suppl 1:63
[Abstract]

68th Scientific Session of the American Diabetes Association, San Francisco
European physicians overestimate life expectancy and the likely impact of interventions in individuals with type 2 diabetes
Price HC, Thorne KI, Dukát A and Kellett J
Diabetes 2008;57:(Suppl 1):A181
[Abstract]

44th Annual Meeting of the European Association for the Study of Diabetes, Rome
Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort
Simmons RK, Coleman RL, Price HC, Holman RR, Khaw KT, Wareham NJ, Griffin SJ
Diabetologia 2008;51:Suppl 1:S549
[Abstract]

44th Annual Meeting of the European Association for the Study of Diabetes, Rome
Characteristics of patients requiring planned modification to regimen allocation during the first year of the 4-T Trial: need for twice-daily basal insulin or addition of a second insulin formulation
Levy JC, Farmer AJ, Thorne KI, Paul SK, Darbyshire JL, Davies MJ, Holman RR
Diabetologia 2008;51:Suppl 1:S387
[Abstract]

68th Scientific Session of the American Diabetes Association, San Francisco
Continuous Glucose Monitoring Results from the Treating to Target in Type 2 Diabetes (4-T) Trial
Davies MJ, Levy JC, Thorne KI, Paul SK, Darbyshire JL, Holman RR.
Diabetes 2008;57:(Suppl 1):A12
[Abstract]

International Biometric Conference, Dublin
A Generalized Autoregressive Conditional Heteroscedasticity Model (GARCH) to Analyze Continuous Blood Glucose Monitoring Data for Diabetic Patients
Sanjoy PK, Holman RR
International Biometric Society 2008;978-0-9821919-0-3
[Abstract]

International Biometric Conference, Dublin
Statistical Analysis of 8-Point Self Measured Capillary Glucose Profiles in Type 2 Diabetic Patients to Compare the Efficacy of Three Different Insulin Regimens
Paul SK, Thorne KI, Holman RR
International Biometric Society 2008;978-0-9821919-0-3
[Abstract]

2007

2nd International Congress on Prediabetes and the Metabolic Syndrome, Barcelona
Does metformin prevent cardiovascular events?
Holman RR
Diabetes & Vascular Disease Research 2007;4:Suppl 1:S26
[Abstract]

2nd International Congress on Prediabetes and the Metabolic Syndrome, Barcelona
Abdominal obesity, metabolic syndrome and global cardiometabolic risk
Holman RR
Diabetes & Vascular Disease Research 2007;4:Suppl 1:S37
[Abstract]

2nd International Congress on Prediabetes and the Metabolic Syndrome, Barcelona
A new era in the secondary prevention of CVD in prediabetes - the Acarbose Cardiovascular Evaluation (ACE) trial
Holman RR
Diabetes & Vascular Disease Research 2007;4:Suppl 1:S40
[Abstract]

2nd International Congress on Prediabetes and the Metabolic Syndrome, Barcelona
The expanding evidence base - what have we added to our understanding of diabetes disease modification?
Holman RR
Diabetes & Vascular Disease Research 2007;4:Suppl 1:S43-S44
[Abstract]

2nd International Congress on Prediabetes and the Metabolic Syndrome, Barcelona
Acarbose Cardiovascular Evaluation (ACE) Trial in prediabetic subjects
Holman RR, Pan CY
Diabetes & Vascular Disease Research 2007;4:Suppl 1:S128
[Abstract]

67th Scientific Session of the American Diabetes Association, Chicago
The Oxford Risk Engine: A Cardiovascular Risk Calculator for Individuals with or without Type 2 diabetes
Coleman RL, Stevens RJ, Holman RR
Diabetes 2007;56:Suppl 1:A170
[Abstract]

The Diabetes UK Annual Professional Conference, Glasgow
Estimating cardiovascular disease risk for individuals with Type 2 diabetes: the new UKPDS Risk Engine
Coleman RL, Stevens RJ, Holman RR
Diabetic Medicine 2007;24:Suppl 1:56
[Abstract]

67th Scientific Session of the American Diabetes Association, Chicago
Life-expectancy in Individuals with Type 2 Diabetes: Implications for Annuities.
Price HC, Cull CA, Clarke PM, Gray AM and Holman RR
Diabetes 2007;56:Suppl 1:A596
[Abstract]

Diabetes UK Annual Professional Conference, Glasgow
Framingham Equations Underestimate Cardiovascular Risk Compared with the UKPDS Risk Engine in People with Type 2 Diabetes.
Price HC, Cull CA, Coleman RL, Stevens RJ and Holman RR
Diabetic Medicine 2007;24:suppl 1:55
[Abstract]

28th Annual Conference of the International Society for Clinical Biostatistics, Alexandroupolis
Modelling Continuous Glucose Monitoring Data: A Statistical Challenge
Paul SK, Holman RR
ISCB Abstracts 2007;117
[Abstract]

43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam
Are measures of adiposity associated independently with incident cardiovascular disease in individuals with newly diagnosed type 2 diabetes?
Coleman RL, Holman RR
Diabetologia 2007;50:Suppl 1:S502
[Abstract]

43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam
Increased incidence of fractures in women who received rosiglitazone in ADOPT (A Diabetes Outcome Progression Trial)
Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G; Diabetes Outcome Progression Trial (ADOPT) Study Group
Diabetologia 2007;50:Suppl 1:S37
[Abstract]

43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam
Greater reductions in C-reactive protein with rosiglitazone than with glyburide or metformin despite greater weight gain
Haffner SM, Kahn SE, Zinman B, Holman R, Viberti GF, Herman WH, Lachin JM, Kravitz BG, Heise MA
Diabetologia 2007;50:Suppl 1:S36
[Abstract]

43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam
The distribution of macular hard exudates is related to future visual acuity in subjects with type 2 diabetes
Stratton IM, Scanlon PH, Holman RR, Stirling RJ, Lipinsk HL, Aldington SJ
Diabetologia 2007;50:Suppl 1:S99
[Abstract]

43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam
Prevalence of glucokinase (GCK) mutations in people with elevated fasting glucose levels: implications for clinical trials
Gloyn AL, van de Bunt M, Stratton I, Tucker L, Lonie L, Ellard S, Holman RR
Diabetologia 2007;50:Suppl 1:S168
[Abstract]

43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam
Determinants of monotherapy failure in ADOPT (A Diabetes Outcome Progression Trial)
Holman RR, Kahn SE, S. Haffner M, Zinman B, Viberti GF, Herman WH, Lachin JM, Kravitz BG, Heise MA
Diabetologia 2007;50:Suppl 1:S356
[Abstract]

43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam
ADOPT: The effectiveness of metformin versus glyburide in type 2 diabetes
Herman WH, Haffner SM, Kahn SE, Zinman B, Holman RR, Viberti GF, Lachin JM, Kravitz BG, Heise MA
Diabetologia 2007;50:Suppl 1:S362
[Abstract]

2006

Diabetes UK Annual Professional Conference, Birmingham
Estimating risk of clinically evident neuropathy in type 2 diabetes: a UKPDS risk equation
Coleman RL, Stevens RJ, Holman RR
Diabetic Medicine 2006;23:Suppl. 2:51

66th Scientific Session of the American Diabetes Association, Washington
Estimating Risk of Clinically Evident Retinopathy in Type 2 Diabetes.
Coleman RL, Stevens RJ, Aldington SJ, Holman RR
Diabetes 2006;55:Suppl 1:A53

27th Annual Conference of The International Society for Clinical Biostatistics, Geneva
Nonparametric regression techniques for inference in highly skewed quality of life data - a case study with LDS diabetes patients using sf-36 scores
Paul SK, Holman RR
ISCB2006 Abstract Book 2006;215

Diabetes UK Annual Professional Conference, Birmingham
Treating to target in Type 2 diabetes (4-T) study of analogue insulin initiation and titration
Farmer AJ, Thorne KA, Stratton IM, Davies M, Keenan J, Teo E, Levy J, Holman RR
Diabetic Medicine 2006;23:Suppl 2:85
[Abstract]

Diabetes UK Annual Professional Conference, Birmingham
LDL cholesterol levels alone do not adequately assess coronary heart disease risk in Type 2 diabetes
Farmer AJ, Paul S, Stratton IM, Tucker L, Neil HAW, Holman RR
Diabetic Medicine 2006;23:Suppl 2:89
[Abstract]

66th Scientific Session of the American Diabetes Association, Washington
LDL Cholesterol Level Alone does not Assess Coronary Heart Disease Risk Adequately in Type 2 Diabetes
Farmer AJ, Paul SK, Stratton IM, Tucker L, Neil AW and Holman RR
Diabetes 2006;55:Suppl 1:A462
[Abstract]

2005

41st Annual Meeting of the European Association for the Study of Diabetes, Athens
Obesity is a major determinant of the association of C-reactive protein levels with the number of metabolic syndrome components in recently diagnosed, drug-naive type 2 diabetes: the ADOPT study cohort
Kahn SE, Zinman B, Viberti G, Kravitz BG, Yu D, Heise MA, Freed MI, the ADOPT Study Group
Diabetologia 2005;48:suppl 1:A249
[Abstract]

41st Annual Meeting of the European Association for the Study of Diabetes, Athens
BMI and ratio of triglycerides to HDL are most predictive of insulin resistance in a drug naive population with type 2 diabetes
Patwardhan R, Lin X, Zambanini A, Eslava S, the ADOPT Study Group
Diabetologia 2005;48:suppl 1:A222
[Abstract]

65th Scientific Sessions of the American Diabetes Association, San Diego
Hepatic enzymes are associated with insulin resistance and impaired fibrinolysis in drug naïve, recently diagnosed type 2 diabetes subjects
Haffner SM, Kahn SE, Heise MA, O'Neill MC, Zinman B, the ADOPT Study Group
Diabetes 2005;54:suppl 1:A255
[Abstract]

65th Scientific Sessions of the American Diabetes Association, San Diego
Obesity is a major determinant of the association of C-reactive protein levels with the number of metabolic syndrome components in type 2 diabetes
Kahn SE, Zinman B, Viberti G, Kravitz BG, Yu D, Heise MA, Freed MI, the ADOPT Study Group
Diabetes 2005;54:suppl 1:A255
[Abstract]

65th Scientific Sessions of the American Diabetes Association, San Diego
A Cardiovascular Risk Calculator for Type 2 Diabetes
Coleman RL, Stevens RJ, Matthews DR, Holman RR
Diabetes 2005;54:Suppl 1:A172

41st Annual Meeting of the European Association for the Study of Diabetes, Athens
Incident nephropathy in type 2 diabetes: a UKPDS Risk Equation
Coleman RL, Stevens RJ, Holman RR
Diabetologia 2005;48:Suppl 1:A32

41st Annual Meeting of the European Association for the Study of Diabetes, Athens
FPG and HbA1c are independent risk factors for microvascular but not macrovascular complications in newly diagnosed type 2 diabetes
Kim JI, Stevens RJ, Holman RR
Diabetologia 2005;48:Suppl 1:A33
[Abstract]

41st Annual Meeting of the European Association for the Study of Diabetes, Athens
Susceptibility for latent autoimmune diabetes in adults (LADA) is determined by variation at the IDDM2 (insulin-gene) locus in white Caucasian patients from UK repositories
Desai M, Zeggini E, Owen KR, Holman RR, Levy JC, Hattersley AT, Hitman GA, Walker M, McCarthy MI, Clark A
Diabetologia 2005;48:Suppl1:A86
[Abstract]

41st Annual Meeting of the European Association for the Study of Diabetes, Athens
Relationship of autoantibodies to glutamic acid decarboxylase (GADA) to deterioration of glycamic control assessed by therapy progression in latent autoimmune diabetes in adults (LADA) in the UKPDS
Clark A, Desai M, Cull CA, Horton VA, Christie MR, Bingley PJ, Bonifacio E, Levy JC, Holman RR
Diabetologia 2005;48:Suppl 1:A86
[Abstract]

41st Annual Meeting of the European Association for the Study of Diabetes, Athens
Genotype and beta cell response to therapy in a large type 2 diabetic cohort
Powell BL, Stratton IM, Holman RR, McCarthy MI
Diabetologia 2005;48:Suppl 1:A101-A102
[Abstract]

Diabetes UK Annual Professional Conference, Glasgow
AFORRD: a multi-centre trial evaluating potential cardiovascular risk reduction in patients with type 2 diabetes randomised in a factorial design to atorvastatin and/or omega-3 polyunsaturated fatty acids
Farmer AJ,Neil HAW, Holman RR
Diabetic Medicine 2005;22:S2:63
[Abstract]

2004

40th Annual Meeting of the European Association for the Study of Diabetes, Munich
Evaluating SCORE and Framingham fatal coronary heart disease risk equations using UKPDS data
Coleman RL, Stevens RJ, Holman RR
Diabetologia 2004;47:Suppl 1:A42

40th Annual Meeting of the European Association for the Study of Diabetes, Munich
Could non-HDL cholesterol replace total/HDL cholesterol ratio to estimate coronary heart disease risk in the UKPDS risk engine?
Stevens RJ, Coleman RL, Shine BL, Holman RR
Diabetologia 2004;47:Suppl 1:A61
[Abstract]

40th Annual Meeting of the European Association for the Study of Diabetes, Munich
Risk factors for neuropathy in UKPDS
Stratton IM, Holman RR, Boulton AJM
Diabetologia 2004;47:Suppl 1:A47
[Abstract]

40th Annual Meeting of the European Association for the Study of Diabetes, Munich
The haemoglobin glycation index is reproducible in dysglycaemic individual but is not explained by post-challenge plasma glucose levels
Kim JI, Stevens RJ, Holman RR
Diabetologia 2004;47:Suppl 1:A122
[Abstract]

40th Annual Meeting of the European Association for the Study of Diabetes, Munich
GAD65 autoantibody titres at diagnosis in Latent Autoimmune Diabetes in Adults (LADA) differ from Type 1 diabetes (T1D) and together with epitope specificity predict insulin requirement
Desai M, Williams AJK, Horton VA, Bingley PJ, Levy JC, Cull CA, Holman RR, Bonifacio E, Christie MR, Clark A
Diabetologia 2004;47:Suppl 1:A186
[Abstract]

40th Annual Meeting of the European Association for the Study of Diabetes, Munich
Cost utility analysis of intensive blood-glucose control, tight blood pressure control and metformin in patients with Type 2 diabetes
Clarke PM, Gray A, Stevens RJ, Holman RR
Diabetologia 2004;47:Suppl 1:A50
[Abstract]

40th Annual Meeting of the European Association for the Study of Diabetes, Munich
A calculator for HOMA
Holman RR, Hines G, Kennedy I, Stevens RJ, Matthews D, Levy JC
Diabetologia 2004;47:Suppl 1:A222
[Abstract]

2003

18th International Diabetes Federation Congress, Paris
Estimations of the clinical benefit of optimal blood glucose, blood pressure and lipid control in type 2 diabetic patients with the metabolic syndrome
Koro CE, Bowlin S, Sun Y, Gomez-Camineros A, the ADOPT Study Group
Diabetologia 2003;46:Suppl 2:A76
[Abstract]

18th International Diabetes Federation Congress, Paris
Differences in the prevalence of the metabolic syndrome between ethnic groups in recently diagnosed type 2 diabetes in the North American cohort of the ADOPT study
Haffner SM, Zinman B, Kahn SE, Herman WH, Heise MA, O'Neill MC, Porter LE, the ADOPT Study Group
Diabetologia 2003;46:suppl 2:A144
[Abstract]

18th International Diabetes Federation Congress, Paris
Symptoms and health status in a recently-diagnosed type 2 diabetic population: the ADOPT study
Perry A, Herman W, Freed MI, Heise MA, Kravitz B, the ADOPT Study Group
Diabetes Metabolism 2003;29:4S16-4S17
[Abstract]

18th International Diabetes Federation Congress, Paris
Are different clinical practice guidelines associated with regional differences in diabetes care?
Herman WH, Kravitz B, Sun Y, the ADOPT Study Group
Diabetologia 2003;46:suppl 2:A436
[Abstract]

18th International Diabetes Federation Congress, Paris
Prevalence and clinical significance of glutamic acid decarboxylase (GAD) antibodies in recently diagnosed type 2 diabetes in the ADOPT study cohort.
Zinman B, Kahn SE, Haffner SM, Herman W, Heise MA, O'Neill MC, the ADOPT Study Group
Diabetologia 2003;46:suppl 2:A148
[Abstract]

18th International Diabetes Federation Congress, Paris
Prevalence of microalbuminuria in recently diagnosed type 2 diabetes mellitus and its relationship to non-traditional risk factors: observations from the ADOPT study
Viberti G, Freed MI, Holman R, Lachin J, Heise MA, the ADOPT Study Group
Diabetologia 2003;46:suppl 2:A326
[Abstract]

18th International Diabetes Federation Congress, Paris
Lack of concordance of WHO and NCEP criteria for the diagnosis of the metabolic syndrome in recently diagnosed diabetes in North America and Europe in the ADOPT study cohort
Kahn SE, Haffner SM, Zinman B, Heise MA, O'Neill MC, Porter LE, the ADOPT Study Group
Diabetes Metabolism 2003;29:4S32
[Abstract]

18th International Diabetes Federation Congress, Paris
Levels of beta-cell dysfunction and insulin resistance differ between Europeans and North Americans with recently-diagnosed diabetes in the ADOPT study
Holman RR, Kahn SE, Heise MA, Porter LE, Freed MI, the ADOPT Study Group
Diabetologia 2003;46:suppl 2:A198
[Abstract]

63rd Scientific Sessions of the American Diabetes Association, New Orleans
Ethnic differences in the prevalence of the metabolic syndrome in recently diagnosed type 2 diabetes in the North American cohort of the ADOPT study
Haffner SM, Zinman B, Kahn SE, Herman WH, Heise MA, O'Neill MC, Porter LE, the ADOPT Study Group
Diabetes 2003;52:suppl:A220
[Abstract]

63rd Scientific Sessions of the American Diabetes Association, New Orleans
Lack of concordance of NCEP and WHO criteria for the diagnosis of the metabolic syndrome in recently diagnosed diabetes in North America and Europe in the ADOPT study cohort
Kahn SE, Haffner SM, Zinman B, Heise MA, O'Neill MC, Porter LE, the ADOPT Study Group
Diabetes 2003;52:suppl:A222
[Abstract]

63rd Scientific Sessions of the American Diabetes Association, New Orleans
Prevalence of microalbuminuria and its relationship to non-traditional risk factors in recently diagnosed type 2 diabetes mellitus: observations from the ADOPT study
Viberti G, Freed MI, Holman R, Lachin J, Heise MA, the ADOPT Study Group
Diabetes 2003;52:suppl:A190
[Abstract]

63rd Scientific Sessions of the American Diabetes Association, New Orleans
Prevalence and clinical significance of glutamic acid decarboxylase (GAD) antibodies in recently diagnosed type 2 diabetes in the ADOPT study cohort
Zinman B, Kahn SE, Haffner SM, Herman W, Heise MA, O'Neill MC, the ADOPT Study Group
Diabetes 2003;52:suppl:A233
[Abstract]

63rd Scientific Sessions of the American Diabetes Association, New Orleans
The ADOPT study: symptoms and health status in a recently diagnosed type 2 diabetic population
Herman W, Freed MI, Heise MA, Kravitz B, Perry A, the ADOPT Study Group
Diabetes 2003;52:suppl:A263
[Abstract]

63rd Scientific Sessions of the American Diabetes Association, New Orleans
Risk of Heart Failure in Type 2 Diabetes
Coleman R, Stevens RJ, Stratton IM, Adler A, Matthews D, Holman RR
Diabetes 2003;52:Suppl 1:A217

60th Scientific Sessions of the American Diabetes Association, Glasgow
Six-year results from the Early Diabetes Intervention Trial
Holman RR, Blackwell L, Stratton IM, Manley SE, Tucker L, Frighi V
Diabetic Medecine 2003;20:(Suppl 2):15
[Abstract]

2002

62nd Scientific Sessions of the American Diabetes Association, San Francisco
Forecasting Coronary Case Fatality in Type 2 Diabetes: A UKPDS Risk Engine Equation
Stevens RJ, Coleman RL, Adler AI, Stratton IM, Holman RR
Diabetes 2002;51:Suppl 2:A172

38th Annual Meeting of the European Association for the Study of Diabetes, Budapest
The Glycaemic Optimisation Outcomes in Diabetes (GOOD) feasibility study: glucose control and weight gain in a 1 year community-based study
Potts NJ, Dudley CA, Holman RR
Diabetologia 2002;45:Suppl 2:A243
[Abstract]

38th Annual Meeting of the European Association for the Study of Diabetes, Budapest
The effect of nateglinide stimulated insulin secretion on post challenge glucose and lipid metabolism in Type 2 diabetes
Mohanlal N, Holman RR
Diabetologia 2002;45:Suppl 2:A246
[Abstract]

38th Annual Meeting of the European Association for the Study of Diabetes, Budapest
The Glycaemic Optimisation Outcomes in Diabetes (GOOD) feasibility study: early use of combination therapies and insulin in general practice.
Potts NJ, Dudley CA, Holman RR
Diabetologia 2002;45:Suppl 2:A265
[Abstract]

21st Joint Meeting of the British Endocrine Societies, Harrogate
Diabetes and vascular risk
Rury R Holman
Endocrine Abstracts 2002;3:S14

193rd Meeting of the Society for Endocrinology and Society for Endocrinology joint Endocrinology and Diabetes Day, London
The Role of Metformin
RR Holman, IM Stratton
Endocrine Abstracts 2002;4:DS8

2001

37th Annual Meeting of the European Association for the Study of Diabetes, Glasgow
Hypoglycaemia in patients with Type 2 diabetes in the UKPDS
Cull CA, Wright AD, Macleod KM, Holman RR
Diabetologia 2001;44:Suppl 1:A217
[Abstract]

37th Annual Meeting of the European Association for the Study of Diabetes, Glasgow
Autoantibodies to IA2ic and to Phogrin increase the prediction for insulin requirement in patients with Type 2 Diabetes
Bosi E, Locatelli M, Cull CA, Scirpoli M, Bonifacio E, Stratton IM, Holman RR, Bottazzo GF
Diabetologia 2001;44:Suppl 1:A103
[Abstract]

37th Annual Meeting of the European Association for the Study of Diabetes, Glasgow
Altered postprandial responses in type 2 diabetes
Mohanlal N, Holman RR
Diabetologia 2001;44:Suppl 1:A165
[Abstract]

37th Annual Meeting of the European Association for the Study of Diabetes, Glasgow
Calcium/calmodulin dependent Protein Kinase II genes: genomic structure and screening for variants in subjects with type 2 diabetes
Gloyn AL, Desai M, Clark A, Holman RR, Frayling TM, Hattersley AT, Ashcroft SJH
Diabetologia 2001;44:Suppl 1:A88
[Abstract]

37th Annual Meeting of the European Association for the Study of Diabetes, Glasgow
Variation at the insulin VNTR locus but not the CTLA-4 locus is associated with age of onset and need for insulin therapy in latent autoimmune diabetes in adults (LADA)
Horton VA, Stratton IM, Owen R, Holman RR, Levy JC, Clark A
Diabetologia 2001;44:Suppl 1:A75
[Abstract]

2000

36th Annual Meeting of the European Association for the Study of Diabetes, Jerusalem
Sulphonylurea Therapy Over Six Years Does Not Delay Progression To Diabetes
Herlihy OM, Morris RJ, Karunakaran S, Holman RR
Diabetologia 2000;43:Suppl1:A73
[Abstract]

36th Annual Meeting of the European Association for the Study of Diabetes, Jerusalem
Reinforced Healthy Living Advice Over Six Years Does Not Delay Progression To Diabetes
Dyson PA, Mehta Z, Hammersley M, Holman RR
Diabetologia 2000;43:Suppl1:A114
[Abstract]

36th Annual Meeting of the European Association for the Study of Diabetes, Jerusalem
Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS
Cull CA, Wright AD, Holman RR
Diabetologia 2000;43:Suppl 1:A40
[Abstract]

36th Annual Meeting of the European Association for the Study of Diabetes, Jerusalem
Butyrylcholinesterase K variant is associated with type 2 diabetes in UK caucasians
Hashim Y, Shepherd D, Wiltshire S, Clarke A, Holman RR
Diabetologia 2000;43:Suppl 1:A51
[Abstract]

36th Annual Meeting of the European Association for the Study of Diabetes, Jerusalem
Possible prevention of type 2 diabetes with acarbose or metformin over three years
Citroën HA, Tunbridge FKE, Holman RR
Diabetologia 2000;43:Suppl 1:A73
[Abstract]

36th Annual Meeting of the European Association for the Study of Diabetes, Jerusalem
ApoE ε2 and butyrylcholinesterase K variant are associated with coronary heart disease in type 2 diabetes
Horton VA, Groves CJ, Naylor M, Owen R, Wiltshire S, Stratton IM, Green F, Holman RR
Diabetologia 2000;43:Suppl 1:A86
[Abstract]

36th Annual Meeting of the European Association for the Study of Diabetes, Jerusalem
Standardised HbA1c measurements are essential for the management of glycaemia as a risk factor in diabetes
Manley SE, Holman RR
Diabetologia 2000;43:Suppl 1:A232
[Abstract]

60th Scientific Sessions of the American Diabetes Association, San Antonio
Possible Prevention of Type 2 Diabetes with Acarbose or Metformin
Holman RR, North BV, Tunbridge FK
Diabetes 2000;40:(Suppl 1):A111
[Abstract]

1998

34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona
Diabetes in families study: The insulin resistance syndrome segregates into 5 underlying factors in non-diabetic siblings of type 2 diabetic patients.
Morris RJ, Levy JC, Barrow BA, Ross IJ, Turner RC
Diabetologia 1998;41:Suppl 1:A70
[Abstract]

34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona
Insulin VNTR and HLA DRB1/DQB1 loci affect age of presentation of autoimmune diabetes in adults
Horton VA, Stratton IM, Owen RJ, Bennett ST, Todd JA, Holman RR, Turner RC
Diabetologia 1998;41:Suppl 1:A105
[Abstract]

34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona
Screening of SUR 1 and KIR6.2 promoters for mutations in different types of type 2 diabetes
Gloyn AL, Hashim Y, Turner RC
Diabetologia 1998;41:Suppl 1:A108
[Abstract]

34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona
Hepatocyte nuclear factor-4α (MODY1) gene mutations in late-onset type 2 diabetics in the UK
Shepherd DE, Hashim Y, Turner RC
Diabetologia 1998;41:Suppl 1:A111
[Abstract]

34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona
Paraoxonase polymorphism MET-LEU 54 is associated with fatal myocardial infarction in type 2 diabetic patients
Groves CJ, Horton VA, Ritchie A, Owen RJ, Stratton IR, Green FR, Holman RR, Turner RC
Diabetologia 1998;41:Suppl 1:A115
[Abstract]

34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona
Elevated proinsulin but not amyloid polypeptide accompanies declining ß-cell function in type 2 diabetes
McNamara CM, Clark A, Turner RC
Diabetologia 1998;41:Suppl 1:A169
[Abstract]

34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona
Hyperglycaemic siblings of type 2 diabetic patients have greater central obesity than their normoglycaemic siblings but similar physical activity indices.
Herlihy OM, Barrow BA, Levy JC, Wareham NJ, Turner RC
Diabetologia 1998;41:Suppl 1:A212
[Abstract]

34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona
Retinopathy in subjects with increased fasting plasma glucose levels.
Karunakaran S, Aldington S, North B, Ryder R, Holman RR
Diabetologia 1998;41:Suppl 1:A283
[Abstract]

34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona
Genetic predisposition to vascular complications of diabetes
Izmajlowicz ML, Groves C, Horton V, Owen R, Stratton I, Turner RC, Green FR
Diabetologia 1998;41:Suppl 1:A353
[Abstract]

34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona
In normoglycaemic siblings of type 2 diabetic patients, obesity accounts for decreased insulin sensitivity but not for hypertension
Levy JC, Morris RJ, Barrow BA, Ross IJ, Turner RC
Diabetologia 1998;41:Suppl 1:A70
[Abstract]

34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona
Hepatocyte nuclear factor 1-alpha (MODY 3) gene mutations in type 2 diabetics of different ethnicity
Hashim Y, Shepherd DE, Li J, Chan J, Turner RC
Diabetologia 1998;41:Suppl 1:A114
[Abstract]

1976

Medical Research Society Meeting 1976,
A New Approach to the Treatment of Mild Diabetes
Holman RR, Turner RC
Clinical Science 1976;p18
[Abstract]

Medical Research Society Meeting 1976,
Beta Cell Deficiency in Maturity Onset Diabetes
Turner RC, Holman RR, Hockaday TDR
Clinical Science 1976;p18
[Abstract]

12th Annual Meeting of the European Association for the Study of Diabetes, Helsinki
A New Approach to the Treatment of Mild Diabetes
Holman RR, Turner RC
Diabetologia 1976;12:398-399
[Abstract]